# Intensity Therapeutics, Inc.: financial statements, quarterly

INTS · Nasdaq · CIK 1567264 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ints.md) · [Financials](/companies/ints/financials.md) · [Filings](/companies/ints/filings.md) · [Insiders](/companies/ints/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ints/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [1,352](/filings/0001567264-24-000052.md) | [1,801 d](/filings/0001567264-25-000010.md) | [2,815](/filings/0001567264-25-000039.md) | [3,563](/filings/0001567264-25-000077.md) | [2,151](/filings/0001567264-25-000103.md) | [1,967 d](/filings/0001567264-26-000024.md) | [2,189](/filings/0001567264-26-000046.md) | [1,541](/filings/0001567264-26-000059.md) | [1,553](/filings/0001567264-25-000103.md) | [1,502 d](/filings/0001567264-26-000024.md) | [1,195](/filings/0001567264-26-000046.md) | [1,833](/filings/0001567264-26-000059.md) |
| Operating income | $k | [(2,491)](/filings/0001567264-24-000052.md) | [(3,352) d](/filings/0001567264-25-000010.md) | [(4,743)](/filings/0001567264-25-000039.md) | [(5,069)](/filings/0001567264-25-000077.md) | [(3,570)](/filings/0001567264-25-000103.md) | [(3,203) d](/filings/0001567264-26-000024.md) | [(3,394)](/filings/0001567264-26-000046.md) | [(2,705)](/filings/0001567264-26-000059.md) | [(2,733)](/filings/0001567264-25-000103.md) | [(3,140) d](/filings/0001567264-26-000024.md) | [(2,526)](/filings/0001567264-26-000046.md) | [(3,084)](/filings/0001567264-26-000059.md) |
| Interest expense | $k | [0.0](/filings/0001567264-24-000052.md) | [(0.2) d](/filings/0001628280-24-011207.md) | [0.0](/filings/0001567264-24-000010.md) | [0.0](/filings/0001567264-24-000041.md) | [0.0](/filings/0001567264-24-000052.md) | [0.0 d](/filings/0001567264-25-000010.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,329)](/filings/0001567264-24-000052.md) | [(3,172) d](/filings/0001567264-25-000010.md) | [(4,603)](/filings/0001567264-25-000103.md) | [(4,971)](/filings/0001567264-25-000103.md) | [(3,513)](/filings/0001567264-25-000103.md) | [(3,181) d](/filings/0001567264-26-000024.md) | [(3,347)](/filings/0001567264-26-000059.md) | [(2,537)](/filings/0001567264-26-000059.md) | [(2,671)](/filings/0001567264-25-000103.md) | [(3,051) d](/filings/0001567264-26-000024.md) | [(2,434)](/filings/0001567264-26-000059.md) | [(3,007)](/filings/0001567264-26-000059.md) |
| Diluted EPS | $ per share | [(0.17)](/filings/0001567264-24-000052.md) | not reported | [(0.34)](/filings/0001567264-25-000039.md) | [(0.36)](/filings/0001567264-25-000077.md) | [(0.25)](/filings/0001567264-25-000103.md) | not reported | [(5.51)](/filings/0001567264-26-000046.md) | [(3.36)](/filings/0001567264-26-000059.md) | [(0.06)](/filings/0001567264-25-000103.md) | not reported | [(0.96)](/filings/0001567264-26-000046.md) | [(1.11)](/filings/0001567264-26-000059.md) |
| Basic EPS | $ per share | [(0.17)](/filings/0001567264-24-000052.md) | not reported | [(0.34)](/filings/0001567264-25-000039.md) | [(0.36)](/filings/0001567264-25-000077.md) | [(0.25)](/filings/0001567264-25-000103.md) | not reported | [(5.51)](/filings/0001567264-26-000046.md) | [(3.36)](/filings/0001567264-26-000059.md) | [(0.06)](/filings/0001567264-25-000103.md) | not reported | [(0.96)](/filings/0001567264-26-000046.md) | [(1.11)](/filings/0001567264-26-000059.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.7](/filings/0001213900-23-085791.md) | [8.6](/filings/0001567264-25-000010.md) | [7.5](/filings/0001567264-24-000010.md) | [3.2](/filings/0001567264-24-000041.md) | [2.8](/filings/0001567264-24-000052.md) | [2.6](/filings/0001567264-26-000024.md) | [0.9](/filings/0001567264-25-000039.md) | [2.2](/filings/0001567264-25-000077.md) | [7.1](/filings/0001567264-25-000103.md) | [11.9](/filings/0001567264-26-000059.md) | [10.2](/filings/0001567264-26-000046.md) | [9.5](/filings/0001567264-26-000059.md) |
| Current assets | $m | [16.6](/filings/0001213900-23-085791.md) | [15.5](/filings/0001567264-25-000010.md) | [11.2](/filings/0001567264-24-000010.md) | [7.4](/filings/0001567264-24-000041.md) | [3.8](/filings/0001567264-24-000052.md) | [3.4](/filings/0001567264-26-000024.md) | [1.7](/filings/0001567264-25-000039.md) | [3.0](/filings/0001567264-25-000077.md) | [8.2](/filings/0001567264-25-000103.md) | [12.7](/filings/0001567264-26-000059.md) | [10.9](/filings/0001567264-26-000046.md) | [11.2](/filings/0001567264-26-000059.md) |
| Total assets | $m | [16.8](/filings/0001213900-23-085791.md) | [17.3](/filings/0001567264-25-000010.md) | [12.4](/filings/0001567264-24-000010.md) | [8.7](/filings/0001567264-24-000041.md) | [5.2](/filings/0001567264-24-000052.md) | [4.8](/filings/0001567264-26-000024.md) | [3.1](/filings/0001567264-25-000039.md) | [4.4](/filings/0001567264-25-000077.md) | [9.6](/filings/0001567264-25-000103.md) | [14.1](/filings/0001567264-26-000059.md) | [12.3](/filings/0001567264-26-000046.md) | [11.5](/filings/0001567264-26-000059.md) |
| Current liabilities | $m | [0.7](/filings/0001213900-23-085791.md) | [4.0](/filings/0001567264-25-000010.md) | [2.5](/filings/0001567264-24-000010.md) | [3.2](/filings/0001567264-24-000041.md) | [2.3](/filings/0001567264-24-000052.md) | [1.8](/filings/0001567264-26-000024.md) | [2.6](/filings/0001567264-25-000039.md) | [2.2](/filings/0001567264-25-000077.md) | [2.3](/filings/0001567264-25-000103.md) | [2.1](/filings/0001567264-26-000059.md) | [2.2](/filings/0001567264-26-000046.md) | [2.2](/filings/0001567264-26-000059.md) |
| Total liabilities | $m | [0.9](/filings/0001213900-23-085791.md) | [4.1](/filings/0001567264-25-000010.md) | [2.7](/filings/0001567264-24-000010.md) | [3.3](/filings/0001567264-24-000041.md) | [2.4](/filings/0001567264-24-000052.md) | [1.9](/filings/0001567264-26-000024.md) | [2.7](/filings/0001567264-25-000039.md) | [2.3](/filings/0001567264-25-000077.md) | [2.4](/filings/0001567264-25-000103.md) | [2.2](/filings/0001567264-26-000059.md) | [2.3](/filings/0001567264-26-000046.md) | [2.3](/filings/0001567264-26-000059.md) |
| Shareholders' equity | $m | [15.9](/filings/0001567264-24-000052.md) | [13.2](/filings/0001567264-26-000024.md) | [9.7](/filings/0001567264-25-000103.md) | [5.3](/filings/0001567264-25-000103.md) | [2.8](/filings/0001567264-25-000103.md) | [2.9](/filings/0001567264-26-000059.md) | [0.3](/filings/0001567264-26-000059.md) | [2.2](/filings/0001567264-26-000059.md) | [7.2](/filings/0001567264-25-000103.md) | [11.9](/filings/0001567264-26-000059.md) | [10.0](/filings/0001567264-26-000059.md) | [9.2](/filings/0001567264-26-000059.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,119) d](/filings/0001567264-24-000052.md) | [(946) d](/filings/0001567264-25-000010.md) | [(4,366)](/filings/0001567264-25-000039.md) | [(4,214) d](/filings/0001567264-25-000077.md) | [(3,972) d](/filings/0001567264-25-000103.md) | [(2,668) d](/filings/0001567264-26-000024.md) | [(1,989)](/filings/0001567264-26-000046.md) | [(2,456) d](/filings/0001567264-26-000059.md) | [(2,387) d](/filings/0001567264-25-000103.md) | [(2,401) d](/filings/0001567264-26-000024.md) | [(1,826)](/filings/0001567264-26-000046.md) | [(2,340) d](/filings/0001567264-26-000059.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2022-09-30) | period not labelled (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3.4](/filings/0001213900-23-085791.md) | [3.4](/filings/0001567264-24-000010.md) | [3.5](/filings/0001567264-24-000041.md) | [13.7](/filings/0001567264-24-000052.md) | [13.7](/filings/0001567264-25-000039.md) | [13.7](/filings/0001567264-25-000077.md) | [13.8](/filings/0001567264-25-000103.md) | [0.6](/filings/0001567264-26-000046.md) | [0.8](/filings/0001567264-26-000059.md) | [43.0](/filings/0001567264-25-000103.md) | [2.5](/filings/0001567264-26-000046.md) | [2.7](/filings/0001567264-26-000059.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,264,879 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001567264-26-000059.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.